AstraZeneca and insitro announced on Oct. 15, 2026, a strategic drug discovery collaboration and licensing agreement that ...
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a ...
As GLP-1 therapies evolve from single-agonist peptides toward dual and triple agonists, formulation and CMC teams face a more ...
The death of a pioneer in molecular genetics recalls age-old questions about social fitness to ensure the ethical uses of scientific advances.
The FDA’s Rare Disease Framework Initiative brings risk-based CMC review and pre-approval inspections into scope for sponsors ...
In the latest installment of the PharmTech AI Pulse Check video series, Associate Editorial Director Christopher Cole is ...
PharmTech covered one of the industry’s biggest events this week, as CPHI Milan was in full force with experts arguing that ...
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral ...
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating ...
On October 14, 2026, the FDA expanded the approved use of Anktiva (nogapendekin alfa inbakicept-pmln), given with Bacillus Calmette-Guérin (BCG), to include adults with high-grad ...
Access Part 1 of this interview in which Scarboro explains why real-world usability belongs at product definition. Access ...
The FDA's expanding embrace of new approach methodologies (NAMs) is forcing pharmaceutical manufacturing and quality teams to rethink how preclinical and CMC data will be generated, validated, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results